Gritstone Oncology Announces Updated Presentation Time at Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

Gritstone Oncology (Nasdaq: GRTS) announced that Andrew Allen, M.D., Ph.D., will present a company overview at the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. Gritstone is focused on developing next-generation cancer immunotherapies against multiple cancer types. Its proprietary Gritstone EDGE platform and individualized neoantigen-based immunotherapy, GRANITE, are key components of its strategy. The live webcast will be accessible on their website, with an archived replay available for 30 days post-event.

Positive

• Gritstone is developing advanced cancer immunotherapies, potentially enhancing treatment options.
• The proprietary Gritstone EDGE platform allows for personalized treatment based on tumor-specific neoantigens.

Negative

• None.

EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview on Thursday, September 17, 2020 at 8:00 a.m. ET during the Cantor Virtual Global Healthcare Conference.

A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at https://ir.gritstoneoncology.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone Oncology
Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGE^TM, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors. The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone’s BiSAb program is currently in lead optimization. For more information, please visit gritstoneoncology.com.

Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com

Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhouselsa.com

 

FAQ

When will Gritstone Oncology present at the Cantor Virtual Global Healthcare Conference?

Gritstone Oncology will present on September 17, 2020, at 8:00 a.m. ET.

What is Gritstone Oncology's focus in the biopharmaceutical industry?

Gritstone Oncology focuses on developing next-generation cancer immunotherapies for various cancer types.

Where can I watch the Gritstone Oncology presentation?

The presentation can be viewed as a live webcast on Gritstone Oncology's website.

What are the key products being developed by Gritstone Oncology?

Gritstone is developing GRANITE and SLATE, immunotherapies based on tumor-specific neoantigens.